| 武云强张威王琰龙铟郝晓柯刘家云△.新型抗凝血药物的研究进展[J].,2012,12(16):3198-3200 |
| 新型抗凝血药物的研究进展 |
| Research Progress of Novel Anticoagulants |
| |
| DOI： |
| 中文关键词: 抗凝血药物 凝血酶抑制剂 水蛭素 凝血因子抑制剂 |
| 英文关键词: Anticoagulant drugs Thrombin inhibitor Hirudin Blood coagulation factor inhibitor |
| 基金项目:国家" 重大新药创制" 科技重大专项（2009ZX09103-669），国家自然科学基金项目（81073095） |
|
| 摘要点击次数: 802 |
| 全文下载次数: 1767 |
| 中文摘要: |
| 当前临床上主要的抗凝血药物如肝素、华法林及重组水蛭素等存在出血，需要实验室监测，药物半衰期短等不足。以pegmusirudin
、HD1-22、flovagatran、otamixaban、RB-006、EP217609 等为代表的新型抗凝血药物克服了现有抗凝剂的诸多不足，为抗
凝和溶栓治疗提供了更多选择。本文就相关研究及进展进行综述。 |
| 英文摘要: |
| The current anticoagulants available to clinicians such as heparin, warfarin and recombinant hirudins (i.e. bivalirudin,
desirudin, lepirudin) have some drawbacks including heparin-induced bleeding, need of laboratory monitoring of warfarin and short
half-life of hirudin in vivo. Novel parenteral anticoagulants in development representative by pegmusirudin, HD1-22, flovagatran,
otamixaban, RB-006, EP217609 overcome the shortcoming of anticoagulants available now. They provide more alternatives to anticoagulant
therapy and thrombolytic therapy. The review addresses the advance of novel anticoagulants in development. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
